1. OS10.6 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study. (6th September 2019) Authors: Lassman, A B; Sepúlveda-Sánchez, J M; Cloughesy, T; Gil-Gil, J M; Puduvalli, V K; Raizer, J; De Vos, F Y; Wen, P Y; Butowski, N; Clement, P; Groves, M D; Belda-Iniesta, C; Steward, K; Moran, S; Ye, Y; Roth, P Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗